Cagrilintide Reconstitution Calculator

A long-acting amylin analog in late-stage clinical trials, typically studied in combination with semaglutide (CagriSema).

Informational only. Not medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any protocol.

Reconstitution calculator

Cagrilintide

Syringe type
Your dose
Draw 48 units
That's 0.48 mL of your reconstituted solution · Concentration 2,500 mcg/mL
This vial gives you 4 doses at 1,200 mcg
010203040506070809010048 units
Math is open source · Educational use only · Not medical advice

About Cagrilintide

Investigational drug. Not FDA-approved. Currently in clinical trials.

Cagrilintide is a long-acting analog of amylin — a peptide hormone co-secreted with insulin by pancreatic beta cells. Amylin signaling contributes to satiety and gastric emptying; cagrilintide was designed to extend native amylin's short half-life into a once-weekly-dosable profile. Most published data explores cagrilintide in combination with semaglutide ("CagriSema"), where the two compounds act on distinct but complementary receptor systems.

Half-life is approximately 8 days (192 hours). Trial dose range is 1.2 mg to 4.5 mg once weekly. Cagrilintide is NOT FDA-approved; it remains investigational as of 2026. CagriSema combination phase-3 trials (REDEFINE program) are ongoing.

Frequently asked questions

What is CagriSema?
CagriSema is a combination of cagrilintide and semaglutide, both dosed once weekly. The REDEFINE phase-3 trial program is studying the combination for obesity and type 2 diabetes. Combination results have shown greater body weight reduction than semaglutide alone in phase-2 data.
Is cagrilintide the same as amylin?
Cagrilintide is a synthetic analog of amylin with modifications that extend half-life to once-weekly dosing. Native amylin has a half-life of ~15 minutes, unsuitable for weekly dosing.
When might CagriSema be approved?
Phase-3 readouts are expected through 2026–2027. An FDA approval decision is estimated for 2027–2028 if trial outcomes support the filing.

Sources

  1. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management." Lancet. 2021. PMID: 33957065
  2. Lau DCW, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity." Lancet. 2021. PMID: 34774193

Related calculators

The app runs every compound.

This page runs one. My Pep Calc runs your whole stack — reconstitution math feeds your dose log, which feeds your site rotation map and the half-life chart. First 500 founders get Lifetime Pro for $149.

See the Founders offer →